Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Zhang

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Nature Communications|June 8, 2021
Sam68 promotes hepatic gluconeogenesis via CRTC2Aijun Qiao, Junlan Zhou, Shiyue Xu, et al.
Journal of Molecular and Cellular Cardiology|October 23, 2019
Sam68 impedes the recovery of arterial injury by augmenting inflammatory responseShuling Han, Shiyue Xu, Junlan Zhou, et al.
Theranostics|August 2, 2021
Ablation of lncRNA <i>Miat</i> attenuates pathological hypertrophy and heart failureLiu Yang, Jianxin Deng, Wenxia Ma, et al.
Journal of Molecular and Cellular Cardiology|June 16, 2026
Retraction notice to 'Sam68 impedes the recovery of arterial injury by augmenting inflammatory response' [Journal of Molecular and Cellular Cardiology 137 (2019) 82-92]Shuling Han, Shiyue Xu, Junlan Zhou, et al.
JTO Clinical and Research Reports|January 26, 2026
Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 TrialNiels Reinmuth, Sébastien Couraud, Luis Paz-Ares, et al.
Circulation Research|January 24, 2018
E2F1 Suppresses Oxidative Metabolism and Endothelial Differentiation of Bone Marrow Progenitor CellsShiyue Xu, Jun Tao, Liu Yang, et al.
The Journal of Clinical Endocrinology and Metabolism|January 9, 2021
Plasma Lipidomic Profiles and Risk of Diabetes: 2 Prospective Cohorts of HIV-Infected and HIV-Uninfected IndividualsEric Zhang, Jin Choul Chai, Amy A Deik, et al.
The Journal of Experimental Medicine|July 26, 2022
Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphomaYu Rebecca Miao, Kaushik Thakkar, Can Cenik, et al.
Future Oncology (London, England)|May 15, 2025
Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancerLuis G Paz-Ares, Oscar Juan-Vidal, Giannis S Mountzios, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2024
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 StudyLuis G Paz-Ares, Oscar Juan-Vidal, Giannis S Mountzios, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Nature Communications|June 8, 2021
Sam68 promotes hepatic gluconeogenesis via CRTC2Aijun Qiao, Junlan Zhou, Shiyue Xu, et al.
Journal of Molecular and Cellular Cardiology|October 23, 2019
Sam68 impedes the recovery of arterial injury by augmenting inflammatory responseShuling Han, Shiyue Xu, Junlan Zhou, et al.
Theranostics|August 2, 2021
Ablation of lncRNA <i>Miat</i> attenuates pathological hypertrophy and heart failureLiu Yang, Jianxin Deng, Wenxia Ma, et al.
Journal of Molecular and Cellular Cardiology|June 16, 2026
Retraction notice to 'Sam68 impedes the recovery of arterial injury by augmenting inflammatory response' [Journal of Molecular and Cellular Cardiology 137 (2019) 82-92]Shuling Han, Shiyue Xu, Junlan Zhou, et al.
JTO Clinical and Research Reports|January 26, 2026
Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 TrialNiels Reinmuth, Sébastien Couraud, Luis Paz-Ares, et al.
Circulation Research|January 24, 2018
E2F1 Suppresses Oxidative Metabolism and Endothelial Differentiation of Bone Marrow Progenitor CellsShiyue Xu, Jun Tao, Liu Yang, et al.
The Journal of Clinical Endocrinology and Metabolism|January 9, 2021
Plasma Lipidomic Profiles and Risk of Diabetes: 2 Prospective Cohorts of HIV-Infected and HIV-Uninfected IndividualsEric Zhang, Jin Choul Chai, Amy A Deik, et al.
The Journal of Experimental Medicine|July 26, 2022
Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphomaYu Rebecca Miao, Kaushik Thakkar, Can Cenik, et al.
Future Oncology (London, England)|May 15, 2025
Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancerLuis G Paz-Ares, Oscar Juan-Vidal, Giannis S Mountzios, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2024
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 StudyLuis G Paz-Ares, Oscar Juan-Vidal, Giannis S Mountzios, et al.
Pageof 8